GlassScriptPhysician profile
Colette Brooks
NPI 1083362396
$9,309.50
in general payments reported to CMS, 2019-2025
34 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,961 · 2023: $3,208 · 2024: $3,930 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,337 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,337.00 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,304.74 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $759.83 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $717.12 | 2022-2024 | Evenity, Prolia, Repatha |
| Cequr Corporation | $702.85 | 2022-2025 | Cequr Simplicity |
| Insulet Corporation | $689.60 | 2022-2024 | Omnipod |
| Corcept Therapeutics | $642.17 | 2022-2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $537.35 | 2022-2024 | |
| Lilly USA, LLC | $530.24 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $488.05 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $432.59 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $348.03 | 2022-2024 | |
| Abbvie INC. | $255.33 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $250.45 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $241.14 | 2023-2025 | Unithroid |
| Ibsa Pharma INC. | $213.65 | 2023-2024 | Tirosint, Tirosint, Licart |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $167.84 | 2022-2024 | Minimed 780g |
| Dexcom, INC. | $135.75 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.06 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $124.58 | 2022-2023 | Steglatro |
| Astrazeneca Pharmaceuticals LP | $102.21 | 2022 | |
| Pfizer INC. | $85.38 | 2024 | |
| Alexion Pharmaceuticals, INC. | $73.13 | 2022-2024 | Strensiq |
| Antares Pharma, INC. | $58.68 | 2024 | Xyosted |
| Recordati_rare_diseases_inc. | $51.93 | 2023-2024 | Signifor Lar, Isturisa |
| Becton, Dickinson and Company | $42.57 | 2022 | |
| Tolmar, INC. | $40.89 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $38.40 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Embecta Corp. | $31.63 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amarin Pharma, INC. | $30.46 | 2022 | |
| Lifescan, INC. | $28.12 | 2022 | |
| Kyowa Kirin, INC. | $16.01 | 2024 | Crysvita |
| Amphastar Pharmaceuticals, INC. | $15.55 | 2024 | |
| Currax Pharmaceuticals LLC | $13.59 | 2022 | |
| Beta Bionics, INC. | $13.58 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colette Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.